Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) can affect your menstrual cycle. Cycle changes reported on GLP-1 medicines include irregular timing, lighter or heavier flow, and in some cases missed periods — most commonly linked to rapid weight loss and hormonal shifts rather than a direct drug effect on the reproductive system. These changes are worth understanding before you start. Wegovy is a prescription-only medicine; a clinical assessment decides whether it is appropriate for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first thing to know is that Wegovy's effect on periods is mostly indirect. Fat tissue produces and stores oestrogen; as your body composition changes, oestrogen levels shift too. A drop of 5–10% of body weight can be enough to alter the regularity, length or heaviness of a cycle. This is not unique to Wegovy, it happens with any intervention that produces meaningful weight loss.
That hormonal recalibration can also work in the other direction. Women who previously had irregular cycles related to excess weight, or to conditions such as polycystic ovary syndrome (PCOS), sometimes find their cycle becomes more regular as weight falls. PCOS is strongly associated with insulin resistance, and GLP-1 medicines like semaglutide influence insulin signalling, so some improvement in cycle regularity may be an indirect benefit. The NHS overview of semaglutide does not list menstrual disruption as a recognised side effect of the medicine itself, which supports the view that the hormonal shifts are metabolic rather than pharmaceutical.
In short: changes to your period on Wegovy are real, but they are almost always a consequence of the treatment working, not a warning sign that something has gone wrong.
This is where the two main GLP-1 medicines differ in one practical way. Wegovy slows gastric emptying, which can theoretically affect how quickly oral medicines are absorbed. NHS England's guidance on weight-management injections notes that, unlike tirzepatide, there is no current evidence that semaglutide reduces the effectiveness of the oral contraceptive pill. Women on tirzepatide are advised to add a barrier method for the first four weeks of treatment and after each dose increase; the equivalent precaution is not stated for semaglutide at present.
That said, the MHRA advises using contraception while on GLP-1 medicines regardless, because fertility can return or increase as weight changes, particularly in women who had reduced fertility before starting. A cycle that returns or becomes more predictable is a positive sign, but it also means ovulation may resume. If pregnancy is not planned, speak to your prescriber about the most reliable contraceptive option for you. A full overview of Wegovy covers the licensed indications and prescribing criteria in more detail.
Most cycle changes on Wegovy settle within a few months as your weight stabilises. Lighter periods, some irregularity in the first few cycles, or a temporary pause are generally not causes for alarm. There are situations, however, that deserve a prompt conversation with a clinician.
Get in touch with your prescriber or GP if: periods stop entirely for three months or more without a clear explanation; bleeding becomes unusually heavy or prolonged; you have significant pelvic pain; or you think you might be pregnant. These could point to causes unrelated to Wegovy that need investigating. Anyone with a history of hormone-sensitive conditions should raise this at their initial consultation before starting treatment.
If you are unsure whether what you are experiencing is within the range of normal, our team is available for aftercare seven days a week. You can also read more about Wegovy and period changes or explore related questions about whether semaglutide can stop your period altogether, both pages go deeper into the evidence and the clinical picture.
Wegovy is not licensed for use in pregnancy or while breastfeeding, and is not recommended for anyone trying to conceive. These exclusions are standard for GLP-1 receptor agonists and are set out in the medicine's Summary of Product Characteristics. If you become pregnant while on treatment, stop taking Wegovy and contact your healthcare team promptly.
The wash-out period before trying to conceive (the time recommended between stopping Wegovy and attempting pregnancy) should be confirmed with your prescriber based on current guidance; it is one of the clinical questions reviewed before any prescription is issued. For broader questions about Wegovy and your situation, our FAQs page covers a range of clinical scenarios, including whether Wegovy changes your taste and how that can affect eating habits over time. Our prescribers also review reproductive health history as part of every assessment of whether Wegovy is suitable, so nothing needs to go unasked.
If you are ready to find out whether Wegovy is clinically right for you, a real prescriber (not an automated system) reads every consultation the same day it arrives. You can check your eligibility through our free online consultation, and if you are currently on a different GLP-1 medicine you can find out how to change to Wegovy and what that process involves. If approved, treatment is dispatched the same day for free next-working-day delivery; the pen arrives in plain, unbranded packaging with a DPD tracking link so you know exactly when to expect it.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.